

Edgar Filing: ENZON PHARMACEUTICALS INC - Form SC 13D/A

ENZON PHARMACEUTICALS INC
Form SC 13D/A
January 28, 2011

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No. 3)*

Enzon Pharmaceuticals, Inc

(Name of Issuer)

Common Stock, \$.01 par value

(Title of Class of Securities)

293904108

(CUSIP Number)

Jeffrey M. Elliott
Executive Vice President
Iridian Asset Management LLC
276 Post Road West
Westport, CT 06880-4704
203-341-9009

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

January 27, 2011

(Date of Event which Requires Filing
of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [].

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the

Edgar Filing: ENZON PHARMACEUTICALS INC - Form SC 13D/A

Notes).

CUSIP No. 293904108

Schedule 13D

Page 2

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Iridian Asset Management LLC

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) [X]

(b) []

3 SEC USE ONLY

4 SOURCE OF FUNDS*

OO

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e) []

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER 0
	8	SHARED VOTING POWER 5,955,267
	9	SOLE DISPOSITIVE POWER 0
	10	SHARED DISPOSITIVE POWER 5,955,267

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

5,955,267

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*

[]

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

10.0%

Edgar Filing: ENZON PHARMACEUTICALS INC - Form SC 13D/A

14 TYPE OF REPORTING PERSON*

IA

CUSIP No. 293904108

Schedule 13D

Page 3

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

COLE Partners LLC

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) [X]

(b) []

3 SEC USE ONLY

4 SOURCE OF FUNDS*

OO

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2 (d) OR 2 (e) []

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF 7 SOLE VOTING POWER
SHARES 0

BENEFICIALLY

OWNED BY
EACH

8 SHARED VOTING POWER
313,520

REPORTING
PERSON
WITH

9 SOLE DISPOSITIVE POWER
0

10 SHARED DISPOSITIVE POWER
313,520

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

313,520

Edgar Filing: ENZON PHARMACEUTICALS INC - Form SC 13D/A

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*

[]

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

0.5%

14 TYPE OF REPORTING PERSON*

HC

CUSIP No. 293904108

Schedule 13D

Page 4

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Iridian Private Business Value Equity Fund, L.P.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) [X]

(b) []

3 SEC USE ONLY

4 SOURCE OF FUNDS*

PF

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e) []

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER 0
	8	SHARED VOTING POWER 221,510
	9	SOLE DISPOSITIVE POWER 0

Edgar Filing: ENZON PHARMACEUTICALS INC - Form SC 13D/A

10 SHARED DISPOSITIVE POWER
221,510

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
221,510

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
[]

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0.4%

14 TYPE OF REPORTING PERSON*
PN

CUSIP No. 293904108

Schedule 13D

Page 5

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Iridian Partners Fund, L.P.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [X]
(b) []

3 SEC USE ONLY

4 SOURCE OF FUNDS*
PF

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2 (d) OR 2 (e) []

6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware

Edgar Filing: ENZON PHARMACEUTICALS INC - Form SC 13D/A

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7 0	SOLE VOTING POWER
	8	SHARED VOTING POWER 92,010
	9	SOLE DISPOSITIVE POWER 0
	10	SHARED DISPOSITIVE POWER 92,010

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
92,010

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
[]

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0.2%

14 TYPE OF REPORTING PERSON*
PN

CUSIP No. 293904108

Schedule 13D

Page 6

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Renoma Partners LLC

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [X]
(b) []

3 SEC USE ONLY

4 SOURCE OF FUNDS*
OO

Edgar Filing: ENZON PHARMACEUTICALS INC - Form SC 13D/A

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2 (d) OR 2 (e) []

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES	7	SOLE VOTING POWER
		0
BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	8	SHARED VOTING POWER
		24,840
	9	SOLE DISPOSITIVE POWER
		0
	10	SHARED DISPOSITIVE POWER
		24,840

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

24,840

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*

[]

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

less than 0.1%

14 TYPE OF REPORTING PERSON*

PN

CUSIP No. 293904108

Schedule 13D

Page 7

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Iridian Charter Fund, L.P.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) [X]
(b) []

Edgar Filing: ENZON PHARMACEUTICALS INC - Form SC 13D/A

3 SEC USE ONLY

4 SOURCE OF FUNDS*

PF

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e) []

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER 0
	8	SHARED VOTING POWER 24,840
	9	SOLE DISPOSITIVE POWER 0
	10	SHARED DISPOSITIVE POWER 24,840

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

24,840

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*

[]

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

less than 0.1%

14 TYPE OF REPORTING PERSON*

PN

1 NAME OF REPORTING PERSON

Edgar Filing: ENZON PHARMACEUTICALS INC - Form SC 13D/A

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Harold J. Levy

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) [X]

(b) []

3 SEC USE ONLY

4 SOURCE OF FUNDS*

PN, OO

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e) []

6 CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF SHARES	7	SOLE VOTING POWER 166,535
BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	8	SHARED VOTING POWER 5,955,267
	9	SOLE DISPOSITIVE POWER 166,535
	10	SHARED DISPOSITIVE POWER 5,955,267

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

6,121,802

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*

[]

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

10.2%

14 TYPE OF REPORTING PERSON*

IN

Edgar Filing: ENZON PHARMACEUTICALS INC - Form SC 13D/A

CUSIP No. 293904108

Schedule 13D

Page 9

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

David L. Cohen

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) [X]

(b) []

3 SEC USE ONLY

4 SOURCE OF FUNDS*

OO

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e) []

6 CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF SHARES	7	SOLE VOTING POWER
		0
BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	8	SHARED VOTING POWER
		5,955,267
	9	SOLE DISPOSITIVE POWER
		0
	10	SHARED DISPOSITIVE POWER
		5,955,267

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

5,955,267

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*

[]

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

Edgar Filing: ENZON PHARMACEUTICALS INC - Form SC 13D/A

10.0%

14 TYPE OF REPORTING PERSON*

IN

CUSIP No. 293904108

Schedule 13D

Page 10

Item 1. Security and Issuer

This Schedule 13D, Amendment No. 3 relates to the common stock, par value \$.01 per share (the "Common Stock"), of Enzon Pharmaceuticals, Inc., a Delaware corporation (the "Issuer").

Issuer's principal executive offices are located at 685 Route 202/206, Bridgewater, NJ 08807.

The information presented on the cover sheets for each filing person is based upon ownership as of March 31, 2010. The percent of class is based upon 59,750,326 shares of Common Stock issued and outstanding as of November 2, 2010 as reported by the Issuer on its Form 10-Q for the period ended September 30, 2010.

This Amendment amends Item 5 of the Schedule 13D previously filed as of March 31, 2010. This Amendment reports a greater than 1% change in beneficial ownership by the Reporting Persons as a result of the increase in the issued and outstanding shares of the Issuer.

Item 5. Interest in Securities of the Issuer.

(a), (b) As of January 27, 2011, the Reporting Persons may be deemed to beneficially own in the aggregate 5,955,267 shares of Common Stock, representing 10.0% of the outstanding Common Stock (the percentage of shares of Common Stock owned being based upon 59,750,326 shares of Common Stock outstanding at November 2, 2010 as set forth in the Issuer's Quarterly Report on Form 10-Q for the period ended September 30, 2010).

The Reporting Persons may be deemed to have direct beneficial ownership of shares of Common Stock as follows:

Name	Number of Shares	Percentage
Iridian (1)	5,616,907	9.4%
Private Business	221,510	0.4%
Partners	92,010	0.2%
Charter	24,840	less than 0.01%
Levy	166,535	0.3%

(1) The shares of Common Stock set forth above for Iridian do not include the shares of Common Stock held by Private Business, Partners and Charter.

Iridian has direct beneficial ownership of the shares of Common Stock in the accounts which it manages. In addition, Iridian is the investment adviser for Private Business. In such capacity, Iridian has the right to vote and direct the disposition of shares of Common Stock held by such entities and, consequently,

Edgar Filing: ENZON PHARMACEUTICALS INC - Form SC 13D/A

has beneficial ownership of such shares.

Messrs. Cohen and Levy may be deemed to possess beneficial ownership of the shares of Common Stock beneficially owned by Iridian by virtue of their indirect controlling ownership of Iridian, and having the power to vote and direct the disposition of shares of Common Stock as joint Chief Investment Officers of Iridian. Messrs. Cohen and Levy disclaim beneficial ownership of such shares.

COLE, as the sole general partner of Private Business and Partners, may be deemed to own beneficially shares of Common Stock of which Private Business and Partners may be deemed to possess direct beneficial ownership. Iridian, as the sole member of COLE, may be deemed to possess beneficial ownership of the shares of Common Stock that are beneficially owned by COLE.

Renoma, as the sole general partner of Charter, may be deemed to own beneficially shares of Common Stock of which Charter may be deemed to possess direct beneficial ownership. Iridian, as the sole member of Renoma, may be deemed to possess beneficial ownership of the shares of Common Stock that are beneficially owned by Renoma.

Iridian has the direct power to vote or direct the vote, and the direct power to dispose or direct the disposition, of 5,955,267 shares of Common Stock. Messrs. Cohen and Levy may be deemed to share with Iridian the power to vote or direct the vote and to dispose or direct the disposition of such shares. Messrs. Cohen and Levy disclaim beneficial ownership of such shares.

Iridian has the direct power to vote or direct the vote, and the direct power to dispose or direct the disposition, of the 221,510 shares of Common Stock held by Private Business and of the 92,010 shares of Common Stock held by Partners. COLE (in addition to Messrs. Cohen and Levy) may be deemed to share with Iridian the power to vote or direct the vote and to dispose or direct the disposition of such shares.

Iridian has the direct power to vote or direct the vote, and the direct power to dispose or direct the disposition, of the 24,840 shares of Common Stock held by Charter. Renoma (in addition to Messrs. Cohen and Levy) may be deemed to share with Iridian the power to vote or direct the vote and to dispose or direct the disposition of such shares.

Levy has the direct power to vote or direct the vote, and the direct power to dispose or direct the disposition, of the 166,535 shares of Common Stock held by him.

(c) Other than the transactions described in Schedule I of this statement, no Reporting Person nor any director or executive officer of any Reporting Person has effected any transactions in the Common Stock during the past 60 days.

(d) No person other than the Reporting Persons has any right to receive or the power to direct the receipt of dividends from, or the proceeds of the sale of, any of the Common Stock beneficially owned by the Reporting Persons, except that the dividends from, or proceeds from the sale of, shares of Common Stock in each respective account managed by Iridian will be delivered into each such respective account.

(e) Not applicable.

SIGNATURE.

After reasonable inquiry and to the best of its or his knowledge and belief, we certify that the information set forth in this statement is true,

Edgar Filing: ENZON PHARMACEUTICALS INC - Form SC 13D/A

complete and correct.

Date: January 28, 2011

IRIDIAN ASSET MANAGEMENT LLC

By: /s/ Jeffrey M. Elliott

Jeffrey M. Elliott, Executive Vice President

COLE PARTNERS LLC

By: /s/ Jeffrey M. Elliott

Jeffrey M. Elliott, Executive Vice President

IRIDIAN PRIVATE BUSINESS VALUE EQUITY FUND, L.P.

By: COLE PARTNERS LLC

By: /s/ Jeffrey M. Elliott

Jeffrey M. Elliott, Executive Vice President

IRIDIAN PARTNERS FUND, L.P.

By: COLE PARTNERS LLC

By: /s/ Jeffrey M. Elliott

Jeffrey M. Elliott, Executive Vice President

RENOMA PARTNERS LLC

By: /s/ Jeffrey M. Elliott

Jeffrey M. Elliott, Executive Vice President

IRIDIAN CHARTER FUND, LP

By: RENOMA PARTNERS LLC

By: /s/ Jeffrey M. Elliott

Jeffrey M. Elliott, Executive Vice President

David L. Cohen

By: /s/ Jeffrey M. Elliott

Jeffrey M. Elliott, Agent

Harold J. Levy

By: /s/ Jeffrey M. Elliott

Jeffrey M. Elliott, Agent

SCHEDULE I
REPORTING PERSONS TRANSACTIONS IN COMMON STOCK

Edgar Filing: ENZON PHARMACEUTICALS INC - Form SC 13D/A

Trade Date	Side	Number of Shares	Price Per Share (1)
11/29/2010	sell	250	\$11.02
11/29/2010	sell	1,300	\$11.02
11/29/2010	sell	700	\$11.02
11/29/2010	sell	1,100	\$11.02
11/29/2010	sell	500	\$11.02
11/29/2010	sell	1,900	\$11.02
11/29/2010	sell	100	\$11.02
11/29/2010	sell	1,000	\$11.02
11/29/2010	sell	200	\$11.02
11/29/2010	sell	600	\$11.02
11/29/2010	sell	400	\$11.02
11/29/2010	sell	400	\$11.02
11/29/2010	sell	600	\$11.02
11/29/2010	sell	200	\$11.02
11/29/2010	sell	200	\$11.02
11/29/2010	sell	400	\$11.02
11/29/2010	sell	300	\$11.02
11/29/2010	sell	100	\$11.02
11/29/2010	sell	1,900	\$11.02
11/29/2010	sell	500	\$11.02
11/29/2010	sell	1,900	\$11.02
11/29/2010	sell	200	\$11.02
11/29/2010	sell	500	\$11.02
11/29/2010	sell	100	\$11.02
11/29/2010	sell	600	\$11.02
11/29/2010	sell	290	\$11.02
11/30/2010	sell	260	\$11.11
11/30/2010	sell	170	\$11.07
12/1/2010	sell	250	\$11.27
12/1/2010	sell	710	\$11.33
12/1/2010	sell	400	\$11.33
12/1/2010	sell	200	\$11.33
12/1/2010	sell	300	\$11.33
12/1/2010	sell	600	\$11.33
12/1/2010	sell	300	\$11.33
12/1/2010	sell	100	\$11.33
12/1/2010	sell	280	\$11.33
12/1/2010	delivered to client	720	
12/1/2010		300	

delivered to client	
12/1/2010delivered to client	1,200
12/1/2010delivered to client	200
12/1/2010delivered to client	300
12/1/2010delivered to client	400
12/1/2010delivered to client	300
12/1/2010delivered to client	100
12/1/2010delivered to client	500
12/1/2010delivered to client	600
12/1/2010delivered to client	300
12/1/2010delivered to client	1,500
12/1/2010delivered to client	900
12/1/2010delivered to client	300
12/1/2010delivered to client	800
12/1/2010delivered to client	1,300
12/1/2010delivered to client	600
12/1/2010delivered to client	1,000
12/1/2010delivered to client	1,600
12/1/2010delivered to client	400
12/1/2010delivered to client	100
12/1/2010delivered to client	300
12/1/2010delivered to client	500
12/1/2010delivered to client	100
12/1/2010delivered to client	1,100
12/1/2010delivered to client	900
12/1/2010	120

delivered to client	
12/1/2010delivered to client	280
12/1/2010delivered to client	700
12/1/2010delivered to client	450
12/1/2010delivered to client	730
12/1/2010delivered to client	130
12/1/2010delivered to client	50
12/1/2010delivered to client	2,250
12/1/2010delivered to client	130
12/1/2010delivered to client	240
12/1/2010delivered to client	30
12/1/2010delivered to client	600
12/1/2010delivered to client	30
12/1/2010delivered to client	640
12/1/2010delivered to client	480
12/1/2010delivered to client	820
12/1/2010delivered to client	1,470
12/1/2010delivered to client	710
12/1/2010delivered to client	120
12/1/2010delivered to client	1,950
12/1/2010delivered to client	820
12/1/2010delivered to client	1,470
12/1/2010delivered to client	20
12/1/2010delivered to client	950
12/1/2010delivered to client	630
12/1/2010	590

Edgar Filing: ENZON PHARMACEUTICALS INC - Form SC 13D/A

	delivered to client	
12/1/2010	delivered to client	480
12/1/2010	delivered to client	620
12/1/2010	delivered to client	110
12/10/2010	sell	40\$11.16
12/16/2010	sell	40\$12.07
12/16/2010	sell	100\$12.07
12/16/2010	sell	100\$12.07
12/16/2010	sell	100\$12.07
12/16/2010	sell	100\$12.07
12/16/2010	sell	100\$12.07
12/16/2010	sell	200\$12.07
12/16/2010	sell	100\$12.07
12/16/2010	sell	190\$12.07
12/17/2010	sell	1,330\$12.00
12/17/2010	sell	400\$12.00
12/17/2010	sell	1,350\$12.00
12/20/2010	sell	1,520\$12.09
12/20/2010	sell	400\$12.09
12/20/2010	sell	200\$12.09
12/20/2010	sell	400\$12.09
12/20/2010	sell	800\$12.09
12/20/2010	sell	400\$12.09
12/20/2010	sell	100\$12.09
12/20/2010	sell	1,700\$12.09
12/20/2010	sell	600\$12.09
12/21/2010	sell	70\$12.12
12/21/2010	sell	100\$12.12
12/21/2010	sell	600\$12.12
12/21/2010	sell	500\$12.12
12/21/2010	sell	300\$12.12
12/21/2010	sell	400\$12.12
12/21/2010	sell	120\$12.12
12/22/2010	sell	800\$12.57
12/22/2010	sell	260\$12.57
12/27/2010	sell	2,990\$12.47
12/27/2010	sell	4,100\$12.47
12/27/2010	sell	1,400\$12.47
12/27/2010	sell	1,400\$12.47
12/27/2010	sell	2,800\$12.47
12/27/2010	sell	2,200\$12.47
12/27/2010	sell	300\$12.47
12/27/2010	sell	8,050\$12.47
12/27/2010	sell	110\$12.51
12/27/2010	sell	50\$12.51
12/27/2010	sell	100\$12.51
12/27/2010	sell	200\$12.51

Edgar Filing: ENZON PHARMACEUTICALS INC - Form SC 13D/A

12/27/2010	sell	40	\$12.50
1/6/2011	sell	100	\$12.49
1/6/2011	sell	700	\$12.49
1/6/2011	sell	1,200	\$12.49
1/6/2011	sell	1,900	\$12.49
1/6/2011	sell	400	\$12.49
1/6/2011	sell	200	\$12.49
1/6/2011	sell	300	\$12.49
1/6/2011	sell	80	\$12.49
1/12/2011	sell	280	\$12.13
1/12/2011	sell	2,200	\$12.19
1/12/2011	sell	2,200	\$12.19
1/12/2011	sell	600	\$12.19
1/12/2011	sell	230	\$12.19
1/13/2011	sell	1,340	\$12.17
1/13/2011	sell	1,900	\$12.17
1/13/2011	sell	600	\$12.17
1/13/2011	sell	800	\$12.17
1/13/2011	sell	140	\$12.17
1/14/2011	delivered to client	310	
1/14/2011	delivered to client	700	
1/14/2011	delivered to client	200	
1/14/2011	delivered to client	600	
1/14/2011	delivered to client	1,000	
1/14/2011	delivered to client	500	
1/14/2011	delivered to client	800	
1/14/2011	delivered to client	900	
1/14/2011	delivered to client	200	
1/14/2011	delivered to client	100	
1/14/2011	delivered to client	200	
1/14/2011	delivered to client	300	
1/14/2011	delivered to client	100	
1/14/2011	delivered to client	600	
1/14/2011	delivered to client	200	
1/14/2011	delivered to client	60	

Edgar Filing: ENZON PHARMACEUTICALS INC - Form SC 13D/A

1/14/2011delivered to client	150
1/14/2011delivered to client	370
1/14/2011delivered to client	240
1/14/2011delivered to client	390
1/14/2011delivered to client	60
1/14/2011delivered to client	20
1/14/2011delivered to client	1,090
1/14/2011delivered to client	60
1/14/2011delivered to client	110
1/14/2011delivered to client	10
1/14/2011delivered to client	280
1/14/2011delivered to client	10
1/14/2011delivered to client	270
1/14/2011delivered to client	200
1/14/2011delivered to client	350
1/14/2011delivered to client	660
1/14/2011delivered to client	310
1/14/2011delivered to client	60
1/14/2011delivered to client	940
1/14/2011delivered to client	400
1/14/2011delivered to client	720
1/14/2011delivered to client	10
1/14/2011delivered to client	410
1/14/2011delivered to client	280
1/14/2011delivered to client	290
1/14/2011	1,610

	delivered to client	
1/14/2011	delivered to client	240
1/14/2011	delivered to client	310
1/19/2011	sell	20\$11.70
1/19/2011	sell	200\$11.70
1/19/2011	sell	100\$11.70
1/19/2011	sell	100\$11.70
1/19/2011	sell	300\$11.70
1/19/2011	sell	100\$11.70
1/19/2011	sell	500\$11.70
1/19/2011	sell	70\$11.70
1/19/2011	sell	370\$11.88
1/24/2011	sell	470\$11.55
1/24/2011	sell	1,200\$11.55
1/24/2011	sell	600\$11.55
1/24/2011	sell	2,800\$11.55
1/24/2011	sell	1,700\$11.55
1/24/2011	sell	500\$11.55
1/24/2011	sell	1,400\$11.55
1/24/2011	sell	240\$11.55
1/24/2011	sell	1,800\$11.63
1/24/2011	sell	200\$11.63
1/24/2011	sell	200\$11.63
1/24/2011	sell	360\$11.63
1/26/2011	sell	410\$11.73
1/26/2011	sell	200\$11.73
1/26/2011	sell	800\$11.73
1/26/2011	sell	100\$11.73
1/26/2011	sell	400\$11.73
1/26/2011	sell	100\$11.73
1/26/2011	sell	300\$11.73
1/26/2011	sell	200\$11.73
1/26/2011	sell	200\$11.73
1/26/2011	sell	300\$11.73
1/26/2011	sell	100\$11.73
1/26/2011	sell	100\$11.73
1/26/2011	sell	200\$11.73
1/26/2011	sell	100\$11.73
1/26/2011	sell	900\$11.73
1/26/2011	sell	200\$11.73
1/26/2011	sell	1,000\$11.73
1/26/2011	sell	100\$11.73
1/26/2011	sell	150\$11.73
1/26/2011	sell	110\$11.68
1/26/2011	sell	40\$11.71
1/26/2011	sell	3,060\$11.71
1/26/2011	sell	2,400\$11.71
1/26/2011	sell	6,850\$11.71

Edgar Filing: ENZON PHARMACEUTICALS INC - Form SC 13D/A

1/27/2011	sell	160	\$11.64
1/27/2011	sell	1,100	\$11.64
1/27/2011	sell	500	\$11.64
1/27/2011	sell	1,800	\$11.64
1/27/2011	sell	100	\$11.64
1/27/2011	sell	1,000	\$11.64
1/27/2011	sell	200	\$11.64
1/27/2011	sell	600	\$11.64
1/27/2011	sell	400	\$11.64
1/27/2011	sell	400	\$11.64
1/27/2011	sell	600	\$11.64
1/27/2011	sell	200	\$11.64
1/27/2011	sell	200	\$11.64
1/27/2011	sell	400	\$11.64
1/27/2011	sell	300	\$11.64
1/27/2011	sell	400	\$11.64
1/27/2011	sell	500	\$11.64
1/27/2011	sell	200	\$11.64
1/27/2011	sell	1,200	\$11.64
1/27/2011	sell	180	\$11.64

(1) Price per share does not include commission.